top of page
Search
COSSAP

Only 1 in 4 adolescent treatment facilities offer buprenorphine for opioid use disorder

NIH-funded study indicates substantial need to expand access to evidence-based treatment among young people

June 13, 2023

Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a new study. Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in access to evidence-based addiction treatment among young people. Published in JAMA, this study was supported by the National Institute on Drug Abuse (NIDA) and the National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health, and led by researchers at Oregon Health & Science University (OHSU).


Comments


bottom of page